[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].Ting Yuan, Qian Jiang, Xiao‐Jun Huang et al.|PubMed|2020Cited by 3
[Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].Ting Yuan, Qianli Jiang, X Y Wang et al.|PubMed|2019Cited by 3